SHSE:600062'
s Net Margin % Range Over the Past 10 Years
Min: 10.27 Med: 12.63 Max: 15.15
Current: 15.15
SHSE:600062's Net Margin % is ranked better than 79.41% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs SHSE:600062: 15.15
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
China Resources Double-Crane Pharmaceutical Co Net Margin % Related Terms
China Resources Double-Crane Pharmaceutical Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co Net Margin % Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co Net Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Net Margin % of 17.28% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is 37% above median its historical median of 12.63. Over the past decade, China Resources Double-Crane Pharmaceutical Co's Net Margin % has ranged from 10.27 to 15.15. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #197 out of 957 companies in the Drug Manufacturers industry, placing it in the top 20.6%.
Is China Resources Double-Crane Pharmaceutical Co's Net Margin % too high?
China Resources Double-Crane Pharmaceutical Co's current Net Margin % of 17.28% is 37% above median its 10-year median of 12.63. Over the past 10 years, this metric has ranged from a low of 10.27 to a high of 15.15. The Drug Manufacturers industry median Net Margin % is 5.58. China Resources Double-Crane Pharmaceutical Co's value of 17.28% is 209.7% above this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #197 out of 957 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #197 out of 957 companies for Net Margin %. This places China Resources Double-Crane Pharmaceutical Co in the top 21% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.58. China Resources Double-Crane Pharmaceutical Co's value of 17.28% is 209.7% above this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own Net Margin % has ranged from 10.27 to 15.15 over the past decade. While the company's 10-year median is 12.63 vs. the industry median of 5.58, China Resources Double-Crane Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current Net Margin % of 17.28% is 209.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current Net Margin % is 17.28%, which is 37% above median its own 10-year median of 12.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.75, compared to a current price of ¥16.43 — trading 12.4% below its estimated fair value. The current Net Margin % is 17.28%, which is 37% above median its 10-year median of 12.63 and 209.7% above the Drug Manufacturers industry median of 5.58. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Net Margin % is 17.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
Net Margin %: 17.28% (37% above median its 10-year median of 12.63)
GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
Industry Position: 209.7% above the Drug Manufacturers median (#197 of 957)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Business Description
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score
Get the complete analysis for SHSE:600062
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
